Purpose: Diverted prescription opioids are significant contributors to drug overdose mortality. Street price has been suggested as an economic metric of the diverted prescription opioid black market. This study examined variables that may influence the street price of diverted oxycodone and oxymorphone. Buyers who purchase large quantities of low potency, large dosage, crush-resistant formulation prescription opioids can expect to achieve the lowest price.
Despite recent evidence investigating the nature and magnitude of prescription opioid diversion in general, data regarding the economic dynamics of the diverted market remain limited. [5] [6] [7] [8] In part, this paucity of data has been attributed to the complexity of the underground diversion system, involving multiple drug sources, 7 a fragmented network of participants, 8 uncertainty about the origins of drugs, 9 differences between cartel-based distribution and local procurement, 10 and fraudulent transactions. 11 Street price, as a quantitative metric of the diverted opioid market, may provide relative and absolute information about the economics of the black market. [12] [13] [14] Further, there is potential for development of supply interdiction policy and intervention evaluation. Yet, very little is known about the factors that influence retail (eg, end user) street prices of diverted prescription opioids.
Previous research examining street price has commonly focused on markets of illicitly manufactured drugs such as heroin, methamphetamine, and marijuana. 15, 16 However, it has been suggested that diverted prescription opioids differ from illicitly manufactured drugs in two important characteristics that may influence their exchange on the black market. First, illicitly manufactured drugs are considered "experience goods", whereby consumers negotiate a price before the product is verified. Because the purity of diverted prescription opioids is known prior to purchase, diverted prescription drug prices may exhibit less variability than illicitly manufactured drugs (where purity is largely based on the seller's description), assuming little market penetration of counterfeit products. Second, some extended-release opioids are available in crush-resistant formulations, whereby a physiochemical barrier deters tampering and subsequent abuse. Unlike black tar heroin in the US, which is also difficult to solubilize, diverted prescription opioids that are tamper deterrent are often found in markets simultaneously with unprotected formulations. These crushresistant formulations may impact desirability on the black market and result in pricing variation. 12 In August 2010, all strengths of OxyContin® (oxycodone ER) were reformulated to be difficult to crush, with a near complete replacement of supply over the following six months. In February 2012, all strengths of Opana ER® (oxymorphone ER) were reformulated as well. 17 These abuse deterrent formulations present a unique opportunity for multivariable exploration of whether street prices for difficult-to-crush opioid analgesics had lower street value than the unprotected formulations, as has been suggested by earlier descriptive studies.
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This study utilized street price data from StreetRx, a website that crowdsources street price data for diverted drugs. An earlier study by our group demonstrated remarkable consistency of street prices for various opioid analgesics between StreetRx, law enforcement officer reports, and actual transaction prices on the "dark web" marketplace, Silk Road. 18 With the closing of the Department of Justice's National Drug Intelligence Center in 2012, the standard government source for street price data, StreetRx offers a validated strategy for collecting street price data.
Using street price data from StreetRx, we sought to examine the factors that influence street prices of diverted oxycodone and oxymorphone with four separate analyses. First, we hypothesized that the relative price of the two opioids would reflect the clinical equianalgesic potency because subjective effects for opioids are largely similar. Second, we expected that the price per milligram would be discounted for larger dosage units of the same opioid molecule, because stronger doses carry marginal additional procurement costs or risks but a lower unit price would result in more sales. Third, we hypothesized that street prices for crush-resistant formulations would be lower than traditional formulations because the former are less pliable for manipulation and injection or snorting.
Fourth, we hypothesized that multi-unit discounts would be apparent for "bulk" purchases, following standard economic theory. 19 2 | METHODS
| Data source
A cross-sectional study was conducted, based on prospective data collection from the public health surveillance crowdsourcing website StreetRx (streetrx.com), in which site users spontaneously and anonymously (eg, no internet protocol addresses are stored) submitted the street prices they paid, or heard were paid, for diverted prescription drugs, described in detail previously. 18 StreetRx users enter the name and dosage of the drug purchased, assisted by a structured list of controlled and non-controlled substances. Geographic specificity is based on user entry of the US state (mandatory) and city (optional 
KEY POINTS
• Prescription opioid street prices are highly variable and influenced by multiple factors.
• Prescription opioids demonstrate predictable price elasticity of potency.
• Quantity discounts for higher dosage strengths result in cheaper street prices.
• Crush-resistant opioids, compared with their crushable equivalents, offer pricing discounts.
• Prescription opioids purchased in bulk, greater than 10 tablets, offer pricing discounts.
| Analysis
The data entry form differentiates between oxycodone and oxymorphone crush-resistant and crushable formulations, with descriptions that include indicia and physical descriptions. Crush-resistant formulations included reformulated OxyContin and Opana ER®.
Crushable formulations included immediate release oxycodone and oxymorphone, original OxyContin (oxycodone ER) and Opana ER (oxymorphone ER), and generic ER oxycodone and oxymorphone.
Reports that could not be distinguished between crush-resistant and crushable formulations, and reports of sales of a product prior to marketing, were excluded from analyses. Analysis was limited to single-entity products as the range in dosage strengths for combination products was much less than the range in single-entity products, potentially confounding the association between strength and price. The primary outcome examined was the price per milligram.
The price data from the StreetRx program were positively skewed; therefore, the price data were log-transformed. Geometric means were used to measure the central tendency of the price data because they approximate the median, which is more representative in price distributions that are not symmetric. Univariate and multivariable linear regression were used to model the log price per milligram and to calculate the 95% confidence intervals (CI) of each of the covariates. Covariates in the multivariable analysis included a yearly date of report as a covariate (for secular time trend), treated as continuous, and was found to be linear. The formulation of the drug product was also considered as a factor possibly associated with price.
Other factors included were whether or not the reporter made a bulk purchase, defined as 10 or more tablets/pills in one transaction, and the dosage strength in milligrams. Dosage strength was log transformed for modeling due to positive skew and standardized so that a one-unit increase in the natural log of dosage strength corresponded with a two-fold increase in milligram strength on the antilog scale. Predicted price was based on the final model assuming the mean of the covariates for each drug. All significance tests were two-sided t-tests and conducted at the 5% level of statistical significance. Analyses were performed using SAS® version 9.4.
3 | RESULTS
| Price and potency
There were 5611 oxycodone reports and 1420 oxymorphone reports analyzed over the study period (Table 1 and oxymorphone 3× more potent than morphine, for a relative potency of 2.0). 20 The predicted relative potency of oxymorphoneto-oxycodone based on the geometric means was 2.1, slightly higher than the clinical standard. 
| Dosage strength trends
There was an inverse relationship between the natural log of price per milligram and the natural log of dosage strength ( (Table 2) . When adjusted for time by year, dosage strength, and bulk purchase, the increased price for crushable oxymorphone products kept its directionality but dropped in magnitude to 41.2% (95% CI: 26.1%, 58.2%, P < 0.001). Therefore, reformulated oxymorphone had double the discount than reformulated oxycodone.
| Bulk purchases
There was a 11.3% (95% CI: −16.1%, −6.2%, P < 0.001) average discount in oxycodone price for multi-unit purchases (eg, "bulk" purchases of more than 10 units) compared with when the purchase was not made in bulk, after adjusting for calendar year, dosage strength, and formulation (Table 2 ). There was a 20.5% (95% CI:
−30.4%, −9.3%, P < 0.001) average discount in oxymorphone price per milligram when the purchase was made in bulk compared with when the purchase was not made in bulk after adjusting for calendar year, dosage strength, and formulation.
| Time
In an unadjusted model, the price of oxycodone products was 4.9% (95% CI: 0.4%, 9.6%, P = 0.035) higher when compared with the year prior ( Table 2) . However, when adjusting for the other covariates, this difference lost significance (2.9%, 95% CI: −1.3%, 7.3%, P = 0.177).
The price of oxymorphone products did not change significantly over the study period in either the univariate (9.0%, 95% CI: −4.2%, 23.9%, P = 0.189) or the multivariable model (2.2%, 95% CI: −9.5%, 15.4%, P = 0.726).
| Predicted price
The most expensive predicted price for oxycodone was $ 
| DISCUSSION
Street prices for prescription opioids are greatly influenced by potency, dosage strength, formulation, and bulk purchasing. By combining low-cost variables, such as higher dosage strength, crushresistant formulations, and bulk purchasing, buyers of prescription opioids can expect to achieve a 68.9% to 69.8% discount.
In contrast to illicitly manufactured drugs, street prices for prescription opioids appear to consistently correlate with clinically established potency across time. 21, 22 We found that the street price of oxymorphone is approximately twice that of oxycodone, which is similar to the oral equianalgesic potency from clinical conversion factors. 20 This relationship is preserved when compared with previous street price data from 2012, even as the street price of oxymorphone and oxycodone has declined over the same period. 18 The remarkable constancy of this correlation suggests that buyers of diverted opioids are discerning in their choice of opioids, and that market efficiency is evident in this aspect. Previous studies have demonstrated that opioid potency is associated with increased rates of non-medical use, as well. 23 While we observed predictable price elasticity of potency for oxycodone and oxymorphone, further information is needed to understand trends for other opioids on the black market. It is possible that this trend may not exist for some opioids, such as fentanyl, given the black market penetration of illicitly manufactured fentanyl and fentanyl-like products.
Our findings are amongst the first to document a quantity discount in the diverted prescription opioid market, a trend that has been previously described in the market of illicitly manufactured drugs. 24 We report that the price per milligram declined up to 24% and 23% for increasing dosage strengths of single entity oxymorphone and oxycodone, respectively, when adjusted for other covariates. Quantity or "Big Box" retailer discounts are familiar from mainstream consumer markets and often represent mitigated seller costs when goods are sold in large quantities. In the illicit market, previous studies have concluded that 50% of seller costs can be attributed to risk compensation. 21 We posit that higher dosage strengths for diverted prescription opioids an influence is novel, as previous data from both the illicit and diverted prescription drug markets have largely focused on purity and potency as primary drivers of street price. 25 However, the finding of quantity discounts described here is limited by the StreetRx data collection tool, which uses 10 tablets as an arbitrary threshold to define bulk purchases. As a result, our ability to describe more nuanced price-volume dynamics is limited in the current study.
We found that opioid formulation (eg, drug delivery platform) is a significant driver of street price. The observed street prices for crush- of unauthenticated purchases that cannot be validated, but a previous validation study found strong correlation between online sources and law enforcement reports of street prices. 18 Misclassification of products within the StreetRx dataset is also a potential concern. Photo identification and pill descriptions were used to mitigate some of this risk, and we assumed that informed consumers would make discerning purchases. Still, OxyContin could be a synecdoche for all oxycodone products, arising in misclassification.
Geographic price dispersion is not considered in the current analysis but has been identified as an additional variable that may affect street price in the illicit market. 9 Additionally, this study does not link street price changes to public health or clinical outcomes. On an individual level, we are not able to control for temporally proximal drivers of drug use which may affect the price willing to be paid;
for example, an individual in active withdrawal may be more elastic in the upper bound of what they will pay to alleviate symptoms.
Finally, the lack of a statistically significant association between time and price may be due to the relatively short study duration utilized in the analysis. Future research is needed to determine street price trends over time.
Street prices for prescription opioids are highly variable and influenced by multiple factors including potency, dosage strength, formulation, and bulk purchasing. Buyers of prescription opioids who purchase large quantities of lower potency, crush-resistant formulations in larger dosage strengths can expect to achieve the lowest price per milligram. With nuanced application, street price remains a promising metric for monitoring the diverted prescription opioid market.
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